1 / 6

Atrial Fibrillation Market Worth USD 16.2 Billion by 2020 | Hexa Research

The increasing incidences of atrial fibrillation, strokes due to blood clots and brain damages are the major factors driving the global atrial fibrillation market.

Carrol
Download Presentation

Atrial Fibrillation Market Worth USD 16.2 Billion by 2020 | Hexa Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Your Catalyst To a Lucrative Business Atrial Fibrillation Market Analysis, Size, Share, Growth and Forecast to 2020 | Hexa Research “Global atrial fibrillation market is projected to reach nearly USD 16.2 billion by 2020. Growing geriatric population and rising cases of brain damage, atrial fibrillation, and strokes caused by blood clots are factors that propel the industry.” The Global Atrial Fibrillation Market is projected to reach nearly USD 16.2 billion by 2020. Growing geriatric population and rising cases of brain damage, atrial fibrillation, and strokes caused by blood clots are factors that propel the industry. People suffering from atrial fibrillation (AF) are given blood thinning & anti-clotting medicines. Based on the level of severity, this cardiovascular condition is of three types, namely, paroxysmal, persistent, and permanent. It is generally triggered by pulmonary embolus, hyperthyroidism, obesity, mitral stenosis, hypertension, and even pneumonia. People suffering from AF are five times more prone to strokes and blood clots as against those who are perfectly healthy. High incidence of heart diseases and heart failures spurs demand for minimally invasive & atrial fibrillation procedures. Radiofrequency ablation is a commonly used procedure in young patients whose heart rhythms can be controlled neither with medicines nor with cardio version. Innovations in radiofrequency ablation, like remotely acquired computed tomography has contributed significantly to the overall industry. Another key driver is the ill effects of unhealthy lifestyle habits, such as smoking and drinking. Browse Details of Report@ https://www.hexaresearch.com/research-report/atrial-fibrillation-industry Follow Us:

  2. Your Catalyst To a Lucrative Business Procedures and regions are two key parameters based on which the global Atrial Fibrillation Market is segmented. According to the former, the industry is bifurcated into pharmacological drugs and non- pharmacological procedures. Pharmacological drugs are of two types, namely, anti arrhythmic and coagulant. Non-pharmacological procedures involve diagnosis using procedures, such as catheter ablation, maze surgery, and electric cardioversion. These procedures do not employ drugs of any sort. Besides lowering the chances of strokes, maze surgeries eliminate the need for life-long treatments based on anti-coagulants. Owing to high rate of success in treating arrhythmia, surgical catheter ablation holds the largest share in the global industry. There are a number of procedures in surgical catheter ablation. The extensively used ones are radiofrequency catheter ablation and microwave catheter ablation. Besides smaller cardiac incisions, these procedures ensure quick recoveries. Geographically, the worldwide Atrial Fibrillation Market is divided into Asia Pacific, North America, Europe, and Rest of the World. In terms of revenue, North America led the global industry in 2013. Regional drivers are a huge patient population inflicted by heart ailments, sophisticated medical infrastructure, and favorable reimbursement frameworks. Heightened awareness about non-pharmacological procedures is yet another prominent driver. It is however expected that Asia Pacific will expand robustly over the forecast period (2012 to 2020). The region is propelled by surging healthcare expenditure and widespread patient awareness. Prominent companies in the global atrial fibrillation market are Bristol Myers Squibb Corporation, Boehringer Ingelheim Gmbh, Sanofi Aventis, Boston Scientific Corporation, and Johnson & Johnson Ltd. Most market competitors focus greatly on innovations that enhance the efficiency of atrial fibrillation diagnostics. After almost of decade of in-depth research, researchers from Hospital Gregorio Marañón and the Polytechnic University of Valencia in Madrid have developed an effective treatment for AF. This system geolocates cardiac arrhythmias in real time. Such a feature guides doctors during cardiac ablations thereby reducing the duration & costs associated with surgical interventions for AF. This novel technology creates a map of the patient’s cardiac activity taking place in the two atria in real time. Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/medical-devices-industry Follow Us:

  3. Your Catalyst To a Lucrative Business Table of Content of Atrial Fibrillation Market Chapter 1. Executive Summary 1.1. Atrial fibrillation - Industry Summary & Critical Success Factors (CSFs) Chapter 2. Atrial fibrillation Industry Outlook 2.1. Market Segmentation 2.2. Market Size and Growth Prospects 2.3. Atrial fibrillation Market Dynamics 2.3.1. Market Driver Analysis 2.3.2. Market Restraint Analysis 2.4. Key Opportunities Prioritized 2.5. Industry Analysis - Porter's 2.6. Atrial fibrillation - Company Market Share Analysis, 2013 2.7. Atrial fibrillation Market PESTEL Analysis, 2013 Chapter 3. Atrial fibrillation Procedures Outlook 3.1. Pharmacological Drugs 3.1.1. Global Pharmacological Drugs for Atrial Fibrillation demand, 2012 - 2020 (USD Million) 3.1.1.1. Global Pharmacological Drugs Market demand, 2012 - 2020 (USD Million) 3.1.1.2. Anti-arrhythmic Drugs Market demand, 2012 - 2020 (USD Million) 3.1.1.3. Anti-coagulant Drugs Market demand, 2012 - 2020 (USD Million) 3.2. Non-Pharmacological Procedures 3.2.1. Global Catheter Ablation Procedures demand, 2012 - 2020 (USD Million) 3.2.1.1. Radiofrequency Catheter Ablation demand, 2012 - 2020 (USD Million) 3.2.1.2. HIFU Catheter Ablation demand, 2012 - 2020 (USD Million) 3.2.1.3. Catheter Cryoablation demand, 2012 - 2020 (USD Million) 3.2.1.4. Microwave Catheter Ablation demand, 2012 - 2020 (USD Million) 3.2.1.5. Laser Catheter Ablation demand, 2012 - 2020 (USD Million) 3.2.2. Global Maze Surgery demand, 2012 - 2020 (USD Million) 3.2.3. Global Electric Cardioversion demand, 2012 - 2020 (USD Million) Chapter 4. Atrial fibrillation Regional Outlook 4.1. North America 4.1.1. North America atrial fibrillation market revenue by procedure, 2012 - 2020 (USD Million) 4.2. Europe Follow Us:

  4. Your Catalyst To a Lucrative Business 4.2.1. Europe atrial fibrillation market revenue by procedure, 2012 - 2020 (USD Million) 4.3. Asia Pacific 4.3.1. Asia Pacific atrial fibrillation market revenue by procedure, 2012 - 2020 (USD Million) 4.4. RoW 4.4.1. RoW atrial fibrillation market revenue by procedure, 2012 - 2020 (USD Million) Chapter 5 Company Profiles 5.1 AtriCure Inc. 5.1.1 Company overview 5.1.2 Financial Performance 5.1.3 Product Benchmarking 5.1.4 Strategic Initiatives 5.2 Biosense Webster Inc. 5.2.1 Company overview 5.2.2 Product Benchmarking 5.2.3 Strategic Initiatives 5.3 Boehringer Ingelheim GmbH 5.3.1 Company overview 5.3.2 Financial Performance 5.3.3 Product Benchmarking 5.3.4 Strategic Initiatives 5.4 Boston Scientific Corporation 5.4.1 Company overview 5.4.2 Financial Performance 5.4.3 Product Benchmarking 5.4.4 Strategic Initiatives 5.5 Bristol- Myers Squibb Corporation 5.5.1 Company overview 5.5.2 Financial Performance 5.5.3 Product Benchmarking 5.5.4 Strategic Initiatives 5.6 Cardio Focus Inc. 5.6.1 Company overview 5.6.2 Financial Performance 5.6.3 Product Benchmarking 5.6.4 Strategic Initiatives Follow Us:

  5. Your Catalyst To a Lucrative Business 5.7 Endoscopic Technologies Inc. 5.7.1 Company overview 5.7.2 Financial Performance 5.7.3 Product Benchmarking 5.7.4 Strategic Initiatives 5.8 Sanofi Aventis 5.8.1 Company overview 5.8.2 Financial Performance 5.8.3 Product Benchmarking 5.8.4 Strategic Initiatives 5.9 St. Jude Medical Inc. 5.9.1 Company overview 5.9.2 Financial Performance 5.9.3 Product Benchmarking 5.9.4 Strategic Initiatives 5.10 Johnsons & Johnson Ltd 5.10.1 Company overview 5.10.2 Financial Performance 5.10.3 Product Benchmarking 5.10.4 Strategic Initiatives Chapter 6. Methodology and Scope 6.1. Research Methodology 6.2. Research Scope & Assumption 6.3. List of Data Sources Follow Us:

  6. Your Catalyst To a Lucrative Business About Us: Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Us: Ryan Shaw Hexa Research Felton Office Plaza 6265 Highway 9 Felton, California 95018 United States Phone: +1-800-489-3075 Email: sales@hexaresearch.com Website - http://www.hexaresearch.com/ Visit Our Blog - hexaresearch1.blogspot.com Follow Us:

More Related